Remedy Pharmaceuticals’ New Website Spotlights Victims of CNS-Related Edema

PRESS RELEASE

Remedy Pharmaceuticals’ New Website Spotlights Victims of CNS-Related Edema

NEW YORK, New York, May 5, 2016 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the Company has launched a new website, CiraraStories.com, which will feature people afflicted by this devastating condition – patients, their families, and the medical professionals who care for them.

The video stories are sponsored by Remedy Pharmaceuticals, makers of CIRARA™, a drug designed to prevent edema formation. 

The inaugural video profiles a remarkable woman, Jaclyn who, at age 32, had a large hemispheric infarction (LHI). The LHI occurred the night before her middle child was to start school for the first time. She had just set out his lunch box, went upstairs, and as she lay down on the bed, a strange sensation came over her. Jaclyn tried getting out of bed, but fell, hitting her head on the nightstand, which woke her husband, Jim. Startled, he jumped out of bed and saw his wife lying on the floor, her head bloodied. Jaclyn was paralyzed on her right side and unable to speak. She could only blink her eyes. Jim called 911. We learn what happened when Jaclyn’s family discovered her chances of surviving were poor, the difficult decision they had to make, and how she is doing now.

“Jaclyn’s story reminds us of the important mission we are on to help CNS-related edema victims to not only survive, but live life to the fullest,” notes David Geliebter, Executive Chairman of Remedy Pharmaceuticals.

ABOUT CIRARA
 
CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to edema, midline shift, increased intracranial pressure and brain herniation, culminating in permanent disability or death. Sur1-Trpm4 channels were discovered by University of Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board member of Remedy Pharmaceuticals. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA.

ABOUT REMEDY PHARMACEUTICALS

Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system (CNS) edema – including large hemispheric infarction and contusional traumatic brain injury, as well as other ischemic injuries and neurological disorders.

ABOUT CIRARASTORIES.COM

CiraraStories may be accessed at www.cirarastories.com. CIRARA is an investigational drug and is not approved for use.  The safety and efficacy of CIRARA has not been established and is currently under investigation. CIRARA stories are presented to create awareness about CNS-related edema.

Contact:

Remedy Pharmaceuticals
Sven Jacobson
212-586-2226 x 225
sven@remedypharmaceuticals.com